Digital therapeutics firm Biofourmis has paid an undisclosed amount to acquire Biovotion, a Switzerland-based wearable health tracker business backed by reinsurer Swiss Re and semiconductor maker STMicroelectronics.
Founded in 2011, Biovotion has created an electronic armband called Everion that monitors 22 physiological indicators in real time, including the user’s blood oxygenation, skin temperature and heart rate.
The product line will be integrated with Biofourmis’ analytics-equipped digital medicine ecosystem, with an upgraded Everion model currently under development to offer more health tracking parameters.
Swiss Re and STMicroelectronics both contributed to Biovotion’s $13.5m series A round in mid-2017, investing alongside Harmony Medical, an investment company backed by asset management group Citic, as well as an unnamed corporate venturing unit and institutional investor.
Swiss Re led the round’s $10.4m first close in 2016, with STMicroelectronics participating as an existing investor.